• In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Comp Growth benchmarks, expanding its presence across key US equity gauges.
• This broad index inclusion makes CRISPR Therapeutics more visible to growth-focused, benchmark-tracking investors, potentially reshaping how the stock fits into diversified biotech allocations.
• With this expanded Russell index presence, we’ll examine how heightened benchmark visibility may influence CRISPR Therapeutics’ investment narrative for investors.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

What Is CRISPR Therapeutics' Investment Narrative?

To own CRISPR Therapeutics, you really have to believe that its gene-editing platform and collaborations can eventually justify years of heavy losses and currently modest revenue of about US$4.10 million. The investment case still turns on clinical milestones, regulatory progress and how effectively the company manages cash burn while remaining unprofitable and forecast to stay that way. The recent broad inclusion in multiple Russell growth indexes mostly affects who holds the stock, not what the business earns, so it does not fundamentally change those near term catalysts. It may, however, add trading liquidity and bring in more benchmark-tracking capital, which can amplify market reactions to good or bad news. With the share price already recovering and trading on a premium price to book, execution risk and funding needs stay front and center.

However, one risk in particular stands out that investors should not ignore. CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Seven Simply Wall St Community fair value estimates, from about US$67.82 to roughly US$214.99, show just how far views can stretch. Set that wide dispersion against CRISPR Therapeutics’ ongoing losses and funding risk, and it becomes clear why you may want to compare several viewpoints before deciding how this stock fits in your portfolio.

Explore 7 other fair value estimates on CRISPR Therapeutics - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CRISPR Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.